Infiltrating myeloid cells in pregnant uteri play critical roles in the establishment of the placenta and maintenance of normal pregnancies. Their recruitment and proliferation are primarily mediated by the interactions of cytokines and chemokines secreted locally with their corresponding receptors. Heme oxygenase-1 (HO-1) has various physiologic properties that contribute to placental vascular development, with deficiencies in HO-1 associated with pregnancy disorders. Here, we investigated the effect of HO-1 on myeloid cell infiltration into pregnant uteri using a partial HO-1-deficient (Het, HO-1
Introduction
During normal pregnancy, myeloid cells, including granulocytes, monocytes/macrophages, and DCs, infiltrate into the uterus (decidua and myometrium), not only to provide the first line of defense against pathogens via innate immunity but also to participate in various processes, such as implantation of the embryo, establishment of the fetoplacental unit, regulation of maternal tolerance to the semiallogeneic fetus, and the induction of labor [1] . An abnormal abundance of infiltrating myeloid cells (either too many or too few) could be a cause of placental malformation and hence, an indicator of pregnancy disorders. For example, an overabundance of macrophages and DCs was found in third-trimester uterine biopsies of preeclamptic women [2, 3] . In addition, the depletion of uterine DCs can result in the failure of implantation and lead to embryo resorption in a mouse model [4] .
From early to midpregnancy, the size of the uterus expands dramatically (;15-fold), whereas the density of infiltrating myeloid cells remains roughly unchanged, suggesting that these cells actively infiltrate into or proliferate in the pregnant uterus [5, 6] . Tagliani et al. [5] elegantly demonstrated that this cell expansion is primarily a result of an infiltration of blood-borne leukocytes or precursors. Their data also suggest that CSF1 (or M-CSF) is at the top of this regulatory hierarchy and couples macrophage with DC population dynamics in the pregnant uterus. It has been hypothesized that CSF1 may function through a direct interaction with its high-affinity receptor tyrosine kinase CSF1R (CD115) or indirectly via the CCR2 receptor and its chemokine ligands, such as MCP1 (CCL2), CCL7, and CCL12 [7] . The infiltration of uterine macrophages has been shown to be CCR2 dependent, whereas DC recruitment is CCR1 and CCR2 independent [5] .
HO-1, also known as heat-shock protein 32, is a cytoprotective protein that has potent antioxidative, anti-inflammatory, and proangiogenic properties [8] [9] [10] . It is the rate-limiting enzyme in the heme degradation pathway that produces equimolar amounts of carbon monoxide, iron, and biliverdin [11] . Deficiencies in the inducible HO-1 isozyme have been reported in human and also established in mouse models. They share similar phenotypic characteristics, such as infertility, prenatal death, severe growth retardation, hemolytic anemia, intravascular hemolysis, increased serum haptoglobin, and renal iron overload [12] [13] [14] [15] . They also display severe chronic inflammation and systemic oxidative stress. The root cause for some symptoms of HO-1 deficiency has been attributed directly to the depletion of tissue macrophages (i.e., in the spleen, liver, and bone marrow) [16] . More interestingly, transplantation of WT macrophages into HO-1 KO (HO-1 2/2 ) mice resulted in a transient engraftment of WT macrophages in the liver and spleen, which subsequently reversed the disease process [17] . All of these findings suggest the importance of HO-1 in macrophage development and function. Even though the role of HO-1 in myeloid cell migration and proliferation has not been fully established, some evidence implicating its involvement has emerged recently. Huang et al. [18] showed that Het macrophages exhibit an impaired migratory response and reduced infiltration into adipose tissue during obesity. Jais et al. [19] also confirmed that HO-1 expression in macrophages is critical in disease progression of diet-induced insulin resistance using conditional HO-1 KO macrophages (Macho mice). Work by Agarwal and coworkers [20] used myeloid-specific, HO-1-deficient (LysM 2/2 ) mice to reveal that HO-1 has a direct role in directing the trafficking of myeloid cells in an acute injury kidney model. Taken together, these studies strongly suggest that myeloid cell trafficking could be affected by myeloid HO-1 expression and independent of the extent of tissue injury or inflammation. HO-1 has also been recognized as an important player in pregnancy [21] [22] [23] [24] [25] [26] . Decreased HO-1 expression in human placentas is found to be associated with recurrent miscarriages, spontaneous abortions, and pre-eclampsia [27] [28] [29] . In the HO-1 KO mouse, females are infertile. In addition, Het pregnancies (HO-1 +/2 3 HO-1 +/2 ) produce smaller litter sizes than that of WT pregnancies, and HO-1 KO embryos are primarily resorbed before E9.5. A partial deficiency in maternal HO-1 not only induces intrauterine growth restriction but also causes severe vascular defects in the placenta, together with significant alterations in angiogenesis in the decidua [30, 31] . Low placental HO-1 expression also significantly alters the morphology and maturation rates of uNK cells and the production of local angiogenic factors and cytokines/chemokines [21, 25, [30] [31] [32] .
In this study, we aimed to investigate the effects of HO-1 on the proliferation and infiltration of myeloid cells in the pregnant uterus. We hypothesized that a partial deficiency in HO-1 would alter both cytokine/chemokine production, as well as the receptor expression of targeted myeloid cells in the pregnant uterus.
MATERIALS AND METHODS

Animals
FVBn mice were purchased from Charles River Laboratories (Wilmington, MA, USA). The FVBn/HO-1/KO mouse strain contains a targeted deletion of a large portion of the HO-1 gene and was generously provided by Dr. Phyllis A. Dennery (Brown University, Providence, RI, USA). The original KO strain was established on a C57BL/6 background and obtained from Poss and Tonegawa [12] . To create this mutation on a FVBn background, C57BL/6 HO-1/KO mice were backcrossed to WT FVBn mice for at least 6 generations. FVBn mice (HO-1 WT or Het) were mated at 6-10 wk of age. All animals were maintained and bred according to institutional guidelines of Stanford University. Gestational ages were calculated by the presence of a vaginal plug as E0.5. Uteri were collected at various gestational ages.
Mouse genotyping. Genotyping was performed by PCR, as described previously [30] . In brief, genomic DNA was isolated from tail cuttings using Preparation of single-cell suspensions from pregnant and nonpregnant uteri
At various gestational ages, pregnant or nonpregnant WT and Het mice were euthanized via CO 2 inhalation. Blood (0.5-1.0 ml) was then collected immediately by intracardiac puncture using a 1 ml syringe fitted with a 28 gauge needle and transferred to Microtainer tubes containing EDTA (BD Biosciences, San Jose, CA, USA). RBCs were lysed using a RBC Lysis Buffer (eBioscience, San Diego, CA, USA). Uteri were then collected as described by Zhao et al. [6] . In brief, uterine horns were identified and then harvested in toto. Blood vessels and connective tissues were then removed. Uteri and placentas were carefully separated from the fetuses. For uterine tissues, the labyrinth (fetal origin) was removed, and any remaining blood was removed by blotting using paper towels. Blanched uteri were then rinsed in MACS buffer (Miltenyi Biotec, San Diego, CA, USA). Uteri were then placed in a small volume of MACS buffer, minced into ;1 mm 3 pieces, and finally pushed through a 60 mm mesh screen (Sigma-Aldrich, St. Louis, MO, USA) using a syringe plunger [33] . The cell suspension was then again filtered using a 70 mm screen.
Multiparameter flow cytometric analyses
Freshly isolated cell suspensions were washed in PBS and incubated with a fixable viability dye (eBioscience), and FcRs were blocked with purified anti-CD16/CD32 (clone 93). Fluorescent-conjugated anti-mouse mAb, e.g., CD45 (30-F11), CD3e (500A2), CD19 (6D5), CD11b (M1/70), CD11c (N418), Ly6-G (RB6-8C5), Ly6-C (HK1.4), CCR1 (643854), CCR2 (SA203G11), CCR3 (J073E5), CXCR4 (2B11), and CSF1R (AFS98), etc., were purchased from eBioscience, BioLegend (San Diego, CA, USA), R&D Systems (Minneapolis, MN, USA), and BD Sciences. Antibody cocktails were then added to FACS buffer and incubated on ice with cells for 30 min. Intracellular staining of HO-1 (HO-1-2; Enzo Life Sciences, Farmingdale, NY, USA) was performed following fixation and permeabilization protocols, as described previously [6] , and according to the manufacturers' instructions (eBioscience). Compensation was done using OneComp eBeads (eBioscience). A BD Biosciences LSRII instrument was used to perform flow cytometry. Percentage of positive cells was calculated against the background set on a fluorescence-minus-one negative control. Analyses of all flow cytometric data were performed using FlowJo (Tree Star, Ashland, OR, USA) software.
In vivo BrdU incorporation studies
A single dose (;2 mg in 10 mg/ml in Dulbecco's PBS/mouse) of BrdU (Sigma-Aldrich) was injected intravenously into pregnant mice (E8.5-E10.5) at 2, 16, or 24 h before they were killed. Single-cell suspensions from bone marrow, blood, and pregnant uteri were prepared, as described above, and stained with surface markers to identify myeloid cell subsets. BrdU incorporation into cells was determined using a BrdU Flow Kit (BD Biosciences), followed by fixation, permeabilization, and intracellular staining using FITC-conjugated mouse anti-BrdU antibodies (BD Biosciences). BrdU + cells were then detected using flow cytometry, as described above.
PCR arrays
Total RNA was extracted from stored (liquid nitrogen) uterine tissues using the RNeasy Mini Kit (Qiagen), as described previously [6] . In brief, cDNA was first synthesized using an RT 2 First Strand Kit (Qiagen 
Statistical analyses
One-way ANOVAs were performed for each set of experiments to determine significant differences (P , 0.05) between experimental groups. Dunnett's tests, which adjusts for multiple comparisons using the same control group, and Mann-Whitney U tests for studies comparing 2 groups were used to determine differences.
RESULTS
HO-1 is predominantly expressed in myeloid cells in WT pregnancies
To study the effect of HO-1 on leukocytes, we first determined HO-1 expression levels in leukocyte subpopulations in the circulation, as well as from uteri of WT mice, at early to midgestation (E8.5-10.5). Leukocyte populations were gated (CD45 + ), and then each subtype was identified as follows: neutrophils (CD11b (Fig. 1A) .
In circulating blood, the highest HO-1 expression was found primarily in myeloid cells, especially in neutrophils and monocytes/macrophages, and was ;10-and ;5-fold greater than that in lymphocytes (T and B cells), respectively ( Fig. 1B and C) . During early pregnancy (;E9.5), the majority of HO-1-positive cells in the uterus resides in the CD45 + population (Fig. 1D ). Similar to that for blood, HO-1 was also predominantly expressed in infiltrating myeloid cells of the uterus, such as neutrophils and monocytes/macrophages ( Fig. 1E and F) . However, nonleukocytes (CD45 2 ) expressed much lower HO-1 and were comparable with that for T and B cells (Fig. 1D ).
Reduced myeloid HO-1 expression is only observed in uteri of pregnant Het mice HO-1 can be induced upon stress, and the state of pregnancy actually creates a stressful circumstance to a woman. To understand how a partial HO-1-deficient state responds to pregnancy, we measured and compared HO-1 expression levels in myeloid cells of pregnant WT (HO-1 +/+ 3 HO-1 +/+ ) and Het (HO-1 +/2 3 HO-1 +/2 ) mice. For reference, myeloid HO-1 expression from virgin Het mice was measured and found to be significantly down-regulated in both blood ( Fig. 2A) and uteri ( Fig. 2B ) compared with virgin WT mice.
During pregnancy, no significant difference was found in blood ( Fig. 2C) , whereas a significant reduction of HO-1 expression (;20-30%) was observed in infiltrating uterine myeloid cells in Het uteri compared with WT uteri (Fig. 2D) .
In addition, a partial deficiency of HO-1 did not induce changes in the populations and phenotypes of any myeloid subtype in blood, suggesting that HO-1 may not affect peripheral myeloid migration, differentiation, or maturation from the bone marrow to the circulation (data not shown).
Infiltrating myeloid cells are significantly reduced in uteri of pregnant Het mice
As during early to midpregnancy, a significant number of myeloid cells infiltrate into the pregnant uterus, we investigated if a reduced expression of HO-1 in myeloid cells would affect their infiltrating ability. To this end, we measured and compared the populations of each infiltrating myeloid subtype in the uteri of pregnant WT and Het females. We found that the total myeloid population, as well as the numbers of neutrophils and monocytes/macrophages, was significantly reduced in pregnant Het uteri at E9.5 6 0.5 ( Fig. 3A-C) . However, the population of DCs was not reduced in pregnant Het uteri (Fig. 3D ).
Limited proliferation of infiltrating myeloid cells in pregnant uteri
To investigate whether the reduction of HO-1-deficient myeloid cells in pregnant uteri was a result of an altered rate of cell proliferation, we performed BrdU (the thymidine analog bromodeoxyuridine) in vivo pulse-labeling assays. A single dose of BrdU (2 mg/mouse) was injected intravenously into mice at 2, 16, and 24 h before they were killed. BrdU only labels dividing cells within a short-time window, as a result of its short half-life in vivo (;2 h). We found that BrdU was primarily incorporated into the dividing Ly6C + population, which represents monocyte precursors (i.e., monoblasts) in bone marrow and monocytes/ macrophages in blood and pregnant uteri (Fig. 4A-C) . Some incorporation of BrdU was identified in DCs and very limited in granulocytes. After 2 h of BrdU administration, newly generated Ly6C + BrdU + cells were only found in the bone marrow (Fig. 4A) and not in blood and uterine tissue ( Fig. 4B and C) , suggesting that Ly6C + cells in the peripheral blood and pregnant uteri were rarely undergoing in situ proliferation, confirming its nonmitotic phenotype in the majority of monocytes outside of the bone marrow. BrdU + cells that were present in blood and pregnant uteri at 16 and 24 h (Fig. 4B and C) are those newly generated cells migrated from the bone marrow.
No significant differences in proliferation rates in bone marrow and migration rates from bone marrow to blood between WT and Het myeloid cells
An in vivo BrdU incorporation assay was used to assess differences in proliferation rates of myeloid cells in the bone marrow between WT and Het pregnancies. Figure 4 shows that BrdU + cells were found in the bone marrow within 2 h of BrdU administration, but rates gradually diminished by 24 h (Fig. 4A) in WT pregnancies. When we compared these rates with Het pregnancies, we found no significant differences in Ly6C + populations at 2 and 16 h (Fig. 5A ), indicating that a partial maternal deficiency of HO-1 did not affect the proliferation rate of monocyte precursor cells. In addition, we further studied whether the migration rates of Ly6C + BrdU + cells from the bone marrow to blood or from blood to uterine tissues were affected by a deficiency in HO-1. No significant differences in the migration of BrdU + -Ly6C + cells from the bone marrow to blood were found between WT and Het pregnancies (Fig. 5B) . However, in pregnant uteri, the total Ly6C + population at 16 h (Fig. 5C ) was reduced significantly in Het pregnant uteri compared with WT. The percentage of BrdU + Ly6C + cells in the total Ly6C + population (Fig. 5D ) was also reduced, although not statistically significant (P = 0.085, 24 h) and probably a result of biological variations from BrdU administration.
Cytokines and chemokines were significantly down-regulated in uteri of pregnant Het mice
Tissue-secreted cytokines and chemokines with chemoattractant properties have been shown to play important roles in myeloid recruitment. To understand if a partial deficiency of HO-1 can affect the production of these factors, we compared gene expression levels of various cytokine and chemokine between uteri of pregnant WT and Het mice ( Table 1) . Of 84 genes screened, we found that several genes were significantly downregulated in pregnant Het uteri at E9.5-10.5 (Table 1) . Cd11b, encoding the panmarker for myeloid cells, was reduced significantly (;6.2-fold), confirming our observed decrease in infiltrating myeloid cells in Het uteri. Cytokines, including Csf1 (M-csf) and Csf3 (G-csf), were also significantly decreased (;4.9-and ;6.5 fold, respectively). In addition, an array of chemokines that are functionally related to mixed leukocyte recruitment (Ccl1, Ccl2, Ccl6, Ccl8, Ccl11, Ccl12, Cxcl9, and Cxcl12), as well as 4 receptors (Ccr1, Ccr2, Ccr3, and Ccr5), was all reduced significantly.
Minimal alterations of CSF1R expression in Het myeloid cells
As CSF1 is one of the top regulators of myeloid recruitment in the pregnant uterus, we investigated how its receptor, CSF1R (CD115), changes during pregnancy. With the use of flow cytometry and antibody-specific mouse CSF1R, we found that WT monocytes/macrophages and DCs expressed higher CSF1R levels than other leukocyte subpopulations (Fig. 6A) . We then compared CSF1R levels of each myeloid subtype from nonpregnant blood, pregnant blood, nonpregnant uteri, and pregnant uteri (Fig. 6B) . We observed a significant increase in CSF1R levels on monocytes/ macrophages and DCs, but not on neutrophils, in blood from pregnant WT mice (E9.5 6 0.5) compared with virgin WT mice, suggesting that more CSF1R-positive cells are recruited from the bone marrow to the circulation in response to pregnancy. On the other hand, CSF1R levels from pregnant uteri actually were lower than blood, indicating that CSF1R may not play a critical role in monocytes and DC recruitment into uteri.
We further compared CSF1R expression on myeloid cells between pregnant WT and Het mice and found that CSF1R was decreased significantly in blood DCs in Het pregnancies (Fig. 6C) . However, no differences of CSF1R myeloid expression were found between pregnant WT and Het uteri (Fig. 6D) , suggesting that HO-1 may not have a direct effect on myeloid infiltration through changes in CSF1R levels.
Altered CCR2 expression in myeloid cells during Het pregnancies
Based on our PCR array data, we studied the expression of other receptors on myeloid cells, such as CCR1, CCR2, CCR3, and CXCR4. As CCR1 and CXCR4 are not highly expressed on myeloid cells, and CCR3 is mostly expressed on eosinophils during pregnancy (data not shown), we focused on CCR2, which has been reported to play a very important role in pregnant uterine macrophage infiltration [5] . In WT pregnancies, we did not find any differences in blood and uterine myeloid cells between nonpregnant and pregnant WT mice, suggesting that pregnancy did not alter myeloid CCR2 expression; however, there was a dramatically increased expression of CCR2 on all subtypes of myeloid cells in uteri of nonpregnant and pregnant mice compared with those in blood (Fig. 7A) , strongly indicating an involvement of CCR2 in the recruitment of uterine myeloid cells.
We then studied how a partial deficiency in HO-1 affected CCR2 expression on myeloid cells. We found no difference in CCR2 expression on circulating myeloid cells between WT and Het pregnancies (Fig. 7B) ; however, we did observe a significant reduction of CCR2 expression on uterine monocytes/macrophages and DCs, but not on neutrophils, of pregnant Het mice compared with those of pregnant WT mice (Fig. 7C) .
DISCUSSION
The infiltration of myeloid cells into the myometrium and decidua during pregnancy facilitates multiple functions throughout gestation. A deficiency of HO-1, however, may negatively impact this process. In this study, we found that HO-1 was predominantly expressed in myeloid cells during pregnancy, and its partial deficiency reduced the infiltration of uterine myeloid cells, especially monocytes/macrophages and neutrophils. The impairment found in Het mice was not the result from a slower in situ proliferation of myeloid cells nor from a decreased myeloid population in the circulating blood but rather, primarily a result of changes in the migration and recruitment of circulating myeloid cells to the uterus. Further studies showed that this was mediated not only by a decreased uterine production of cytokines (CSF1 and CSF3) and various chemoattractant chemokines but also an altered expression of myeloid cell receptors, such as CCR2. The combination of these alterations resulted in a less-sufficient infiltration of myeloid cells into the pregnant uterus, which may likely contribute to defects in placental vascular development that have been previously shown to be associated with Het pregnancies [32, 34, 35] . Even though HO-1 has been shown to be expressed in PBMCs, erythrocytes, and some bone marrow cells [36] , there are no reports that have thoroughly characterized HO-1 expression in leukocyte subpopulations. Therefore, we set out to determine HO-1 expression levels of leukocytes from blood and uteri using flow cytometry. We found that HO-1 was expressed predominantly in myeloid cells in both the blood and uteri, which may explain previous observations reporting defects of myeloid phagocyte function and impaired immunologic responses in humans and mice with HO-1 deficiencies [37, 38] . Interestingly, when we measured the HO-1 levels in circulating and uterine myeloid cells in Het mice, we did not see a 50% reduction, as expected for a heterozygous mutation, but only a 20-30% reduction. In addition, expression levels of HO-1 from circulating myeloid cells were not different between WT and Het pregnancies, suggesting that there may be a compensatory upregulation of HO-1 (or HO-2) in Het mice to maintain myeloid cell function. In the human population, there are interindividual variations in HO-1 expression, manifested either through a GT dinucleotide repeats polymorphism or a mutant allele [14, 28] ; thus, the use of our Het mouse model may reveal underlying mechanisms translatable to the human circumstance. Our PCR array data further revealed that expression of genes encoding many chemotaxic chemokines and receptors was decreased in uteri of pregnant Het mice. These chemokines are produced mainly by the uterine cells, such as decidua stromal cells, residential macrophage, uNK, and myometrium cells, but also, may be partially derived from invasive trophoblast cells originating from the fetal side, although the invasion of trophoblast cells into the decidua is very shallow in the mouse. The gene for CXCL12, produced mostly by trophoblast cells and responsible for the recruitment of peripheral CXCR4 + NK cells and endothelial progenitor cells to pregnant uteri [39] , was significantly reduced (;27-fold) in Het uteri. It may explain our previous findings of a significantly lower number of uNK cells, presence of placental vasculature malformations, smaller litter sizes, and a lower Mendelian ratio (only 5% was full HO-1 KOs vs. the expected 25%) in Het pregnancies [32] . Gene expression for other ligand-receptor pairs were also significantly reduced in Het pregnancies: CCR1 and its ligand (CCL6) are for neutrophil and macrophage differentiation; CCR2 and its ligands (CCL2 and CCL12) are for macrophage recruitment; CCR3 and its ligands (CCL8 and CCL11) are mostly for eosinophil and Th2 trafficking [40] . Abnormal expression of cytokines/chemokines in uteri and receptors on leukocytes are related to pathologic pregnancies. An increased expression of CCL2 and CCL5 in the first trimester is believed to account for the accumulation of macrophages and DCs in pre-eclamptic decidua [41] . Significant decreases in CCR3 and increases in CCR5 on peripheral CD4 + T cells have been shown to be associated with murine miscarriages [42] .
We also found significantly lower expressions of CSF1 and CSF3 in pregnant Het uteri compared with pregnant WT uteri ( Table 1 ), suggesting that HO-1 may regulate their production. The CSF family, including CSF1, CSF2, and CSF3, has been found to be expressed in the reproductive tract and facilitate processes, such as ovulation, embryo implantation, placentation, and embryonic development [7, [43] [44] [45] . In this study, we focused only on CSF1R as an example of cytokine receptor changes in myeloid cells. The CSF1/CSF1R interaction not only stimulates directly the in situ proliferation of myometrial macrophages but also induces macrophage precursor recruitment from the blood. Our receptor expression studies showed that CSF1R increased mostly in the circulating monocytes/macrophages and DCs during pregnancy, implying that they may be involved in the replenishment of circulating cells from the bone marrow under the stress of pregnancy. However, no difference in CSF1R myeloid expression in uteri was found between WT and Het pregnancies, suggesting that a reduction of infiltrating myeloid cells in Het uteri was mainly a result of a decreased production of CSF1 instead of a modification of the receptor.
For monocyte/macrophage recruitment, besides CSF1, CCR2 and its ligands also play important roles [5] . CCR2 is 1 of the very few receptors that is known to mediate the recruitment of maternal myeloid cells into pregnant uteri in the mouse [5] . We found that CCR2 was significantly induced in uterineinfiltrating myeloid cells compared with their blood counterparts, confirming its involvement in myeloid recruitment into pregnant and nonpregnant uteri. We also observed a decreased expression of CCR2 on monocytes/macrophages and DCs, as well as a reduced production of its ligands (CCL2 and CCL12) in pregnant Het uteri, suggesting that HO-1 affects both CCR2 and its ligand.
For neutrophil recruitment into uteri, the mechanism is not well established. The trafficking of neutrophils to tissue has been mostly studied in infected or inflamed tissues [20] but not in noninflamed tissues, such as a pregnant uterus. Here, we found a significant reduction of neutrophil infiltration and CSF3 production in pregnant Het uteri. CSF3, also known as G-CSF, can stimulate the proliferation, differentiation, and migration of neutrophils. Although we did not directly study how HO-1 affects the expression of CSF3R on neutrophils, we do speculate that a deficiency of HO-1 may impair CSF3/CSF3R function and subsequently, negatively affect neutrophil recruitment and cause detrimental changes in placental vascular development.
Even though HO-1 is known to be ubiquitously expressed in cells, HO-1 expression was found predominantly in myeloid cells in uteri during early pregnancy. HO-1 haplodeficiency affects both the uterine microenvironment and myeloid phenotype. Alterations in the recruitment of each myeloid cell subtype to the uterus could be controlled by a master regulator, such as CSF1, but also specifically by different chemokine/receptor pairs. Although, we only explored a few of them, the underlying role(s) of HO-1 in the recruitment and maintenance of infiltrating myeloid cells in the uterus are apparent but still need further investigation, especially in the context of the fetus' genotype, as there may be crosstalk occurring in the fetomaternal interface. This may impact or at least contribute to the overall expression of the myeloid phenotype. Further research in these areas will provide a greater understanding of the role of leukocyte migration and the complexity of the cytokine/chemokine network in normal pregnancy. Figure 7 . HO-1 affects CCR2 expression of infiltrating myeloid cells in the uterus during pregnancy. CCR2 expression was determined in myeloid subtypes using flow cytometry. (A) Significant inductions in CCR2 levels were found in neutrophils, DCs, and monocytes/macrophages in uteri compared with blood from pregnant WT (PR; n = 6) or nonpregnant WT controls (NPR; n = 6). (B) No difference in blood CCR2 expression was found between WT (open bars; n = 6) and Het pregnancies (solid bars; n = 6). (C) Significant reductions were observed in DCs and monocytes/ macrophages in uteri from pregnant Het mice (solid bars; n = 6) compared with that of WT mice (open bars; n = 6). *P , 0.05; ***P , 0.005; ****P , 0.001.
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